Skip to content
Tech News
← Back to articles

Author Correction: Casdatifan shows durable response linked to HIF-2α biology in kidney cancer

read original more articles
Why This Matters

This correction highlights the importance of accurate scientific communication in understanding the role of HIF-2α biology in kidney cancer, which could influence future research and treatment strategies. Clear and precise information ensures that the scientific community and consumers stay informed about advancements in cancer biology and targeted therapies.

Key Takeaways

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

Reprints and permissions